Guillain-Barré syndrome- and Miller Fisher syndrome-associated Campylobacter jejuni lipopolysaccharides induce anti-GM1 and anti-GQ1b Antibodies in rabbits.
Infection and Immunity , Volume 69 - Issue 4 p. 2462- 2469
Campylobacter jejuni infections are thought to induce antiganglioside antibodies in patients with Guillain-Barre syndrome (GBS) and Miller Fisher syndrome (MFS) by molecular mimicry between C. jejuni lipopolysaccharides (LPS) and gangliosides. We used purified LPS fractions from five Campylobacter strains to induce antiganglioside responses in rabbits. The animals that received injections with LPS from GBS-associated strains developed anti-GM1 and anti-GA1 antibodies. Animals injected with LPS from one MFS-related C. jejuni strain produced anti-GQ1b antibodies. Rabbits that were injected with Penner O:3 LPS had a strong anti-LPS response, but no antiganglioside reactivity was observed. The antiganglioside specificity in the rabbits reflected the specificity in the patients from whom the strains were isolated. In conclusion, our results indicate that an immune response against GBS- and MFS-associated C. jejuni LPS results in antiganglioside antibodies. These results provide strong support for molecular mimicry as a mechanism in the induction of antiganglioside antibodies following infections.
|Adult, Animals, Antibodies, Bacterial/*biosynthesis, Campylobacter jejuni/*immunology, Child, Epitopes, G(M1) Ganglioside/*immunology, Gangliosides/*immunology, Guillain-Barre Syndrome/*microbiology, Humans, Immunization, Lipopolysaccharides/*immunology, Male, Middle Aged, Miller Fisher Syndrome/*microbiology, Rabbits, Research Support, Non-U.S. Gov't|
|Infection and Immunity|
|Organisation||Erasmus MC: University Medical Center Rotterdam|
de Klerk, M.A, Endtz, H.P, Jacobs, B.C, Laman, J.D, van der Meché, F.G.A, van Doorn, P.A, & Ang, C.W. (2001). Guillain-Barré syndrome- and Miller Fisher syndrome-associated Campylobacter jejuni lipopolysaccharides induce anti-GM1 and anti-GQ1b Antibodies in rabbits. Infection and Immunity, 69(4), 2462–2469. doi:10.1128/IAI.69.4.2462-2469.2001